BridgeMD
Tests treatment safety and results for COVID-19 Recurrent
Official title COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
ClinicalTrials.gov ID: NCT06168032
What this study is testing
What is Any Chinese government-recommended COVID-19 booster vaccine?
Any Chinese government-recommended COVID-19 booster vaccine is an investigational medicine, being studied as a potential treatment for covid-19 recurrent.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients who agree to participate in the trial and sign the informed consents.
- Male or female, ≥18 years old.
- Diagnosed of lung carcinoma by histological and cytological examinations.
- Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
- Recorded history of COVID19 infection.
You likely can't join if
- Life expectance less than 3 months.
- Less than 3 months since last confirmed COVID-19 infection.
- Patients unable to return the hospital for follow-up.
- Patients allergic to COVID-19 vaccine.
- Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or...
See the full eligibility criteria
- Patients who agree to participate in the trial and sign the informed consents.
- Male or female, ≥18 years old.
- Diagnosed of lung carcinoma by histological and cytological examinations.
- Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
- Recorded history of COVID19 infection.
- Sufficiently functional organs.
- Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.
- Life expectance less than 3 months.
- Less than 3 months since last confirmed COVID-19 infection.
- Patients unable to return the hospital for follow-up.
- Patients allergic to COVID-19 vaccine.
- Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.